Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Leading orphan drugs based on R&D phase III cost 2015

Phase III R&D costs of projected top orphan drugs as of 2015 (in million U.S. dollars)*

by Statista Research Department, last edited Oct 30, 2015
Leading orphan drugs based on R&D phase III cost 2015 This statistic displays the research and development phase III cost of the top 10 drugs based on net present value, as of 2015. Actelion's Uptravi had a total R&D phase III cost of 185 million U.S. dollars. Orphan drugs are used to target rare diseases or disorders, which in the United States is defined as less than 200,000 patients. The development of orphan drugs are currently incentivized in the United States through the Orphan Drug Act of 1983.
Show more

Phase III R&D costs of projected top orphan drugs as of 2015 (in million U.S. dollars)*

R&D Phase III cost in million U.S. dollars
--
--
--
--
--
--
--
--
--
--
R&D Phase III cost in million U.S. dollars
--
--
--
--
--
--
--
--
--
--
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1.5m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $49 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1.5m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $49 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

Download Settings Share
Download started
Please be patient - this may take a moment
by Statista Research Department, last edited Oct 30, 2015
This statistic displays the research and development phase III cost of the top 10 drugs based on net present value, as of 2015. Actelion's Uptravi had a total R&D phase III cost of 185 million U.S. dollars. Orphan drugs are used to target rare diseases or disorders, which in the United States is defined as less than 200,000 patients. The development of orphan drugs are currently incentivized in the United States through the Orphan Drug Act of 1983.
Show more
Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Statista has been my savior on several occasions. The site is easy to maneuver and the data is in a format that can go right into a report or presentation.
Marlene Greenfield

Marlene Greenfield
Vice President, Hearst Magazines

Statistics on "Pharmaceutical industry in Norway "
  • Overview
The most important statistics
  • Production and trade
  • Pharmaceutical turnover
  • R&D, patents and new products
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.